Bausch + Lomb Co. (NYSE:BLCO) Receives $20.25 Average Price Target from Analysts

Shares of Bausch + Lomb Co. (NYSE:BLCO) have earned a consensus recommendation of “Hold” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.25.

A number of brokerages recently issued reports on BLCO. Evercore ISI upgraded shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $19.00 to $25.00 in a report on Tuesday, October 15th. Stifel Nicolaus reduced their price objective on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating on the stock in a research note on Wednesday. Royal Bank of Canada decreased their price objective on Bausch + Lomb from $23.00 to $22.00 and set an “outperform” rating for the company in a report on Wednesday. Wells Fargo & Company lowered their target price on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, January 16th. Finally, Citigroup cut Bausch + Lomb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $24.00 to $22.00 in a research note on Wednesday, December 11th.

Bausch + Lomb Trading Down 1.7 %

Shares of BLCO stock opened at $17.34 on Thursday. Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69. The stock’s fifty day moving average price is $18.29 and its two-hundred day moving average price is $18.15. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The company has a market cap of $6.11 billion, a PE ratio of -16.52, a P/E/G ratio of 2.37 and a beta of 0.47.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period last year, the company posted $0.22 EPS. Equities analysts predict that Bausch + Lomb will post 0.6 EPS for the current fiscal year.

Institutional Trading of Bausch + Lomb

Institutional investors have recently modified their holdings of the company. Blue Trust Inc. grew its holdings in shares of Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock worth $48,000 after acquiring an additional 1,004 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Bausch + Lomb during the fourth quarter valued at $72,000. Squarepoint Ops LLC bought a new stake in shares of Bausch + Lomb in the second quarter worth $173,000. Gordian Capital Singapore Pte Ltd bought a new stake in shares of Bausch + Lomb during the 3rd quarter valued at $289,000. Finally, Polar Asset Management Partners Inc. purchased a new position in Bausch + Lomb during the third quarter valued at approximately $289,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.